MedTrace Logo

Effect of Dapagliflozin on Right Ventricular-Pulmonary Artery Coupling After Off-Pump Coronary Atery Bypass Grafting

NCT07601867 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2026-05-22

No results posted yet for this study

Summary

This prospective, single-center observational study evaluates the effect of dapagliflozin 10 mg/day on right ventricular-pulmonary artery coupling measured by the TAPSE/PASP ratio in 72 patients with left ventricular ejection fraction \<50% after off-pump coronary artery bypass grafting (OPCAB). The primary outcome is the change in TAPSE/PASP ratio from 1 month after surgery (before dapagliflozin) to 7 months after surgery (after 6 months of dapagliflozin therapy).

Conditions

Sponsors & Collaborators

  • Samson Badalyan

    lead OTHER

Principal Investigators

  • Samson S. Badalyan, MD, PhD · City Clinical Hospital, Pyatigorsk, Russia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2027-09-01
Completion
2027-11-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07601867 on ClinicalTrials.gov